Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Palifermin is a modified version of a naturally occurring human growth factor that is
currently approved by the FDA to treat blood cancers. The purpose of this study is to
determine whether palifermin can increase CD4 counts in treatment-experienced HIV infected
adults.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)